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Abstract  
Introduction: The benefits of unsupervised exercise programmes in obstructive lung 
disease are unclear. The aim of this systematic review was to synthesise evidence 
regarding the efficacy of unsupervised exercise versus non-exercise based usual care 
in patients with obstructive lung disease. 
Methods: Electronic databases (MEDLINE, CINAHL, EMBASE, AMED, Web of 
Science, Cochrane Central Register of Controlled Trials, PEDro) and trial registers 
(ClinicalTrials.gov, Current Controlled Trials, UK Clinical Trials Gateway and WHO 
International Clinical Trials Registry Platform) were searched from inception to April 
2020 for randomised trials comparing unsupervised exercise programmes with non-
exercise based usual care in adults with COPD, non-cystic fibrosis bronchiectasis or 
asthma. Primary outcomes were exercise capacity, quality of life, mortality, 
exacerbations, and respiratory-cause hospitalisations. 
Results: Sixteen trials (13 COPD, 2 asthma, 1 chronic bronchitis: 1,184 patients) met 
the inclusion criteria. Only data on COPD populations was available for meta-analysis. 
Unsupervised exercise resulted in a statistically but not clinically significant 
improvement in 6MWT (n=5, MD=22.0 metres, 95% CI 4.4 to 39.6 metres, p=0.01). 
However, unsupervised exercise did lead to statistically significant and clinically 
meaningful improvements in SGRQ (n=4, MD=-11.8 points, 95% CI -21.2 to -2.3 
points, p=0.01) and CRQ domains (Dyspnoea, n=4, MD=0.5 points, 95% CI 0.1 to 0.8 
points, p<0.01; Fatigue, n=4, MD=0.7 points, 95% CI 0.4 to 1.0 points, p<0.01; 
Emotion, n=4, MD=0.5 points, 95% CI 0.2 to 0.7 points, p<0.01; Mastery, unable to 
perform meta-analysis) compared to non-exercise based usual care. 
Discussion: This review demonstrates clinical benefits of unsupervised exercise 
interventions on HRQoL in patients with COPD. High-quality randomised trials are 
needed to examine the effectiveness of prescription methods.  
  
Key Messages 
- What is the key question? – Are unsupervised exercise interventions effective 
for inducing improvements in exercise capacity, quality of life and health care 
utilisation outcomes? 
- What is the bottom line? – Unsupervised exercise interventions are effective 
at improving SGRQ and CRQ domain scores, but do not result in clinically 
meaningful improvements in 6MWT.  
- Why read on? – This systematic review provides a wealth of information on 
interventions used to date as well as synthesised data on commonly used 
clinical outcomes in relation to unsupervised exercise.  
  
Introduction 
There is a strong evidence base showing the effectiveness of supervised exercise 
interventions, such as traditional centre-based pulmonary rehabilitation, for the 
management of obstructive lung disease as demonstrated by improvements in 
symptoms, exercise capacity and quality of life outcomes (1-3). When delivered 
following acute exacerbations of COPD, such supervised interventions also reduce 
hospitalisations (4). Despite these points, relatively few people with obstructive lung 
disease have access to such programmes or may find it difficult to engage with, or 
adhere to, face-to-face exercise programmes delivered in a supervised setting (5, 6). 
Barriers to access and long-term adherence include time requirements, travel 
constraints and the use of specialist equipment which may not be available in the home 
setting (7, 8).  
With the clear benefits of exercise interventions and the issues surrounding 
compliance, it is important to adapt programmes to various patient needs. One 
approach to addressing common barriers with supervised exercise programmes, such 
as time requirements and travel constraints (for both the health care professionals and 
patients), is to tailor programmes to be delivered in the patient’s home in an 
unsupervised manner. Some studies have compared supervised exercise 
programmes to unsupervised programmes (9, 10) and suggest unsupervised 
interventions might be able to offer time, space, and/or cost-effective ways to improve 
exercise adherence, fitness, and symptoms. Whilst there have been systematic 
reviews examining the efficacy of exercise interventions for patients with COPD across 
different settings, they have not specifically examined the efficacy of unsupervised 
exercise versus usual care (11). There is a lack of clarity in the way unsupervised 
exercise interventions are defined (e.g. home‐rehabilitation, tele-rehabilitation or self‐
management programmes) and, to the best of our knowledge, there are no reviews to 
date which have compiled all of the available evidence on unsupervised exercise 
interventions across multiple obstructive lung diseases. Such evidence would provide 
valuable information to health care providers in the management of obstructive lung 
disease, particularly in settings where resources are limited for delivering supervised 
exercise interventions.  
The purpose of this systematic review was to establish an up-to-date synthesis of 
available evidence from randomised controlled trials and derive estimates of effect for 
unsupervised exercise interventions on functional exercise capacity, quality of life, and 
health care use outcomes for people with obstructive lung disease. 
 
Methods  
The protocol for this study (CRD42018092273) was registered in advance on 
PROSPERO (International Prospective Register of Systematic Reviews; 
www.crd.york. ac.uk/PROSPERO/). 
Participants/population 
Adults (i.e. >18 years) with a clinical diagnosis of COPD, non-cystic fibrosis 
bronchiectasis or asthma as defined by authors of the study were included.  
Intervention 
Studies were included if patients were randomised to an unsupervised exercise 
training intervention. For the purposes of this review, exercise was defined as ‘physical 
activity consisting of planned, structured and repetitive bodily movement done to 
improve and/or maintain one or more components of physical fitness’ (12). The 
following criteria were applied for an unsupervised exercise intervention to be 
considered for inclusion: includes aerobic and/or resistance-based exercises; 
evidence of prescription to participants (i.e. FITT principles: frequency, intensity, time, 
and type of exercise); a baseline assessment of exercise performance (if assessing 
exercise capacity as an outcome); can run alongside a supervised or unsupervised 
education programme; can include an introductory supervised 'run in' period of up to 
2 weeks which is for the purposes of demonstration, instruction or familiarisation but 
not a formal supervised programme (e.g. pulmonary rehabilitation); can include remote 
contact with healthcare professionals using technologies such as telephones or 
tablet/smart devices, as long as this does not take place during exercise (i.e. real-time 
instruction/coaching). 
Comparator 
The comparator was any concurrent control group that did not receive an exercise 
intervention (including referral to pulmonary rehabilitation in the study period). Any 
study that had a control arm/usual care of non-exercise-based interventions (e.g. 
education, counselling, breathing/relaxation/airway clearance therapy) was still 
included if the intervention arm also received these treatments. 
Outcomes 
Primary outcomes were exercise performance/capacity (e.g. 6 minute walk test 
(6MWT), incremental shuttle walk test (ISWT), and endurance shuttle walk test 
(ESWT)), health-related quality of life (e.g. St. Georges Respiratory Questionnaire 
(SGRQ), chronic respiratory disease questionnaire (CRQ), hospital anxiety and 
depression score (HADS), and asthma control questionnaire (ACQ)), disease impact 
(COPD assessment tool (CAT)), all-cause mortality, exacerbations, and respiratory-
cause hospitalisations. 
Secondary outcome measures were: all-cause hospitalisations, length of hospital stay, 
emergency department visits, outpatient visits, general practitioner (GP) visits, 
adverse events, aerobic fitness/capacity, peripheral muscle strength, physical activity 
levels (PAL), and activities of daily living. 
Study Design 
Studies were considered for inclusion if they adopted a randomised controlled trial 
design with randomisation of participants at an individual or cluster level, or quasi-
randomised method. Randomised cross-over trials, up to the point of crossover, were 
also eligible.  
Search Strategy 
To identify any relevant ongoing or published systematic reviews, searches were 
conducted using Database of Abstracts of Reviews of Effects (DARE), PROSPERO, 
and the Cochrane Database of Systematic Reviews (CDSR).  
The following bibliographic databases, platforms and trial registers were searched: 
MEDLINE, CINAHL, EMBASE, Web of Science Core Collection, Cochrane Central 
Register of Controlled Trials (CENTRAL), Physiotherapy Evidence Database (PEDro), 
Allied and Complementary Medicine Database (AMED), ClinicalTrials.gov, Current 
Controlled Trials, UK Clinical Trials Gateway and World Health Organisation 
International Clinical Trials Registry Platform. Searches were completed within each 
source from inception to April 2020 with no limits set on language. Attempts were made 
to translate any relevant non-English language texts. These searches were 
supplemented with internet searches (i.e. Google Scholar), Conference Proceedings 
Index (Web of Science), forward and backward citation tracking from included studies, 
review articles and contact with study authors.  
Search terms were structured around the population (e.g. “Lung Diseases, 
Obstructive”), intervention (e.g. “Exercise”) and study type (e.g. “randomised”). An 
example of a full search strategy is presented in Table S1. 
Search results were compiled using EndNote referencing software (Clarivate 
Analytics, Philadelphia, PA, USA). Following removal of duplicate citations, two 
reviewers screened titles and abstracts independently. For studies that were not 
excluded based on title/abstract, full text papers were requested and independently 
assessed by two reviewers for eligibility. Any discrepancies in decisions of study 
eligibility were resolved through discussion, and if required, a third reviewer.  
Data extraction and quality appraisal 
Data extraction was completed using an adapted form on Microsoft Excel based on 
the Cochrane Data Extraction Template. The characteristics and data extracted are 
listed in Table S2. One reviewer undertook data extraction for each study, with the 
accuracy of this extraction cross-checked by a second reviewer.  
Risk of bias (quality) assessment 
Two reviewers independently assessed the risk of bias within the included studies 
using the Cochrane Tool for Risk of Bias in accordance with the Cochrane Handbook. 
The domains evaluated were: selection bias, performance bias, detection bias, attrition 
bias, reporting bias and other bias (13). Each of these domains were categorised as 
having high, low or unclear risk of bias, with the overall risk of bias for each study then 
determined as high (more than two ‘unclear’ or more than one ‘high’ risk domain), 
moderate (two ‘unclear’ or one ‘high’ risk domain), or low (no ‘unclear’ or ‘high’ risk 
domains). Any disagreements in risk of bias assessments were resolved through 
further discussion and, if required, the input of a third reviewer. 
Strategy for data synthesis 
All meta-analyses were performed using Review Manager version 5.4 and in 
accordance with Cochrane guidance (13). We contacted study authors to obtain any 
missing numerical outcome data. In very few cases, where all methods to obtain data 
had been exhausted, estimates of effect for individual studies were extracted from 
previous systematic reviews and guideline documents. Measures of effect were mean 
differences for all continuous outcomes. We focused on changes from baseline to end 
of intervention period for continuous outcomes as this was the method of reporting 
that was most common across studies and to help remove between-person variability 
from the analysis. For individual studies where standard deviation of changes was not 
available we calculated using other reported parameters (e.g. 95% confidence 
intervals), imputed using correlation coefficients derived from other studies in the same 
meta-analysis or assuming a conservative correlation coefficient of 0.5, or (for 
unstandardized mean difference estimates only) opted to use post-intervention values 
only in the analysis. Risk ratios were used for dichotomous outcomes. Individual study 
data for continuous and dichotomous outcomes were combined statistically using an 
inverse random-effects method. Statistical heterogeneity in all meta-analyses was 
interpreted by the I2 value. In meta-analyses where I² statistic was greater than 40% 
potential sources of the statistical heterogeneity were explored. We pre-specified 
subgroup analysis to explore heterogeneity in the primary outcomes according to the 
following clinical and methodological factors: diagnosis (COPD, Bronchiectasis, 
Asthma) and severity of disease; exercise intervention characteristics (FITT principles, 
methods of delivery or support including run-in period); comparator (no intervention or 
non-exercise based intervention); outcome measures (generic or disease-specific, 
objective or self-reported); study design (allocation method/duration of follow up). 
There was only one primary outcome where the I² statistic was greater than 40% and 
could be resolved by our pre-specified subgroups. For this meta-analysis (SGRQ), 
heterogeneity was best explained by exercise intervention characteristics. We did not 
perform subgroup analyses on any other primary outcomes. We also planned to 
perform sensitivity analysis by excluding studies with a moderate or high risk of bias, 
but this was not possible due to a lack of studies with a low risk of bias.  
 
Results 
After duplicates were removed, searches identified 6,240 records for screening, of 
which 4,362 records were excluded based on title and 1,602 on abstract. Full texts 
were obtained for the remaining 276 records of which 16 studies met the inclusion 
criteria (Figure 1).  
Characteristics of included studies 
The sixteen included studies were published between 1977 and 2020 (Table S3). Of 
the included studies, 13 focussed on COPD (14-26), 2 on asthma (27, 28), and 1 on 
chronic bronchitis (29) as an obstructive lung disease. A total of 1,184 obstructive lung 
disease patients (1,055 COPD, 105 asthma, 24 chronic bronchitis) were randomised, 
of which 59% were males. Study sample sizes varied in size between 16 and 191 
patients.  COPD disease severity varied from mild to very severe and asthma from 
mild to moderate.  
All studies were randomised controlled trials, which allocated patients to either a 
control group (usual care) or to an intervention including unsupervised exercise. The 
control group in some studies received educational support (22, 24, 25), telephone 
calls (22, 25, 26), and clinic follow-ups (19, 29) in addition to usual care. The 
unsupervised exercise interventions lasted between 6 weeks to 1 year. Exercise 
sessions varied in session frequency, from 2 days a week to daily exercise. Desired 
exercise intensity was not reported in all studies, but of those which reported set 
exercise intensity, there was variation with exercise programmes ranging from 
moderate to high intensity (16, 18-22, 24, 26). The designed exercise programmes 
covered aerobic, resistance and strength training. The characteristics of included 
studies which were utilised in the meta-analysis have been summarised in Table 1. A 
detailed overview of the characteristics of all eligible studies can be found in Table S3. 
The risk of bias assessment was hindered by poor study reporting (Table S4).
Table 1. Characteristics of included studies in the meta-analysis 
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COPD = Chronic obstructive pulmonary disease, GOLD = Global initiative for chronic obstructive lung disease, 6MWT = 6 minute walk test, HRmax = Maximum heart rate, PR = Pulmonary rehabilitation, 
ISWT = Incremental shuttle walk test. 
Primary Outcomes 
Exercise capacity 
6MWT: Meta-analysis of five trials (17, 18, 22, 25, 26) in COPD patients demonstrated 
a statistically significant improvement in 6MWT performed with unsupervised exercise 
(MD = 22.0 metres, 95% CI 4.4 to 39.6 metres, p = 0.01) (Figure 2A). Statistical 
heterogeneity was not apparent (I2= 0%). However, the magnitude of effect did not 
meet the threshold of 30m for clinically important improvement (30). Four further trials 
reported 6MWT as an outcome (14-16, 20) in a COPD population but data could not 
be obtained from one study (16) and in another three studies (14, 15, 20) data could 
only be retrieved from previous systematic reviews (1, 30, 31). Extraction of trial data 
from previous reviews is not a widely accepted approach but analysis with the 
additional three studies is provided in the supplementary material (Figure S1). Data 
from the three studies had minimal effect on the overall magnitude of effect of 
unsupervised exercise interventions (MD = 25.3 metres, 95% CI -1.0 to 51.5 metres, 
p = 0.06) but their inclusion led to substantial heterogeneity (I2= 71%).    
ISWT: Meta-analysis of four trials (19, 21, 23, 24) in COPD patients demonstrated a 
statistically significant improvement in ISWT performance with unsupervised exercise 
(MD = 19.9 metres, 95% CI 2.6 to 37.2 metres, p = 0.02) (Figure 2B). Statistical 
heterogeneity was not apparent (I2 = 0%). However, the intervention effect was heavily 
weighted towards one trial (26).  
Other reported outcomes: Single trials reported ESWT (23), endurance treadmill test 
(26) and 12MWD (29) as outcome measures in COPD populations, therefore meta-
analyses could not be performed.  
Health-related quality of life and disease impact 
SGRQ: Meta-analysis of four trials (15, 18, 21, 26) in COPD patients showed a 
statistically significant effect on SGRQ-Total (MD = -11.8 points, 95% CI -21.2 to -2.3 
points, p = 0.01) and SGRQ-Impact (MD = -12.0 points, 95% CI -19.7 to -4.2 points, p 
< 0.01) scores with unsupervised exercise, and favoured an intervention effects which 
was not statistically significant for SGRQ-Symptoms (MD = -6.2 points, 95% CI -14.5 
to -2.1 points, p = 0.14) and SGRQ-Activity (MD = -12.8 points, 95% CI -25.9 to -0.3 
points, p = 0.06) scores. However, there was substantial heterogeneity within each 
domain analysis (SGRQ-Total, I2 = 85%, p < 0.01; SGRQ-Impact, I2 = 74%, p < 0.01; 
SGRQ-Symptoms, I2 = 67%, p = 0.03; SGRQ-Activity, I2 = 89%, p < 0.01).  
SGRQ (subgroup analysis): Pre-specified subgroup analysis according to intervention 
period (short-term ≤ 12 weeks vs long-term > 12 weeks) demonstrated a greater 
magnitude of effect with short-term intervention for SGRQ (SGRQ-Total, MD = -15.5 
points, 95% CI -21.9 to -9.2 points, p < 0.01; SGRQ-Impact, MD = -15.4 points, -21.6 
to -9.1 points, p < 0.01; SGRQ-Symptoms, MD = -9.7 points, 95% CI -18.4 to -0.9 
points, p = 0.03; SGRQ-Activity, MD = -18.8 points, 95% CI -24.9 to -12.7 points, p < 
0.01). Heterogeneity was reduced to levels deemed to be unimportant for SGRQ-Total 
(I2 = 33%), SGRQ-Impact (I2 = 25%), and SGRQ-Activity (I2 = 4%). Heterogeneity was 
only reduced to moderate levels with SGRQ-Symptoms (I2 = 44%) (Figures 3A-D). 
One further trial reported SGRQ as an outcome (28) in asthma patients but data could 
not be obtained for meta-analysis. 
CRQ: Meta-analysis of four trials (19, 22-24) in COPD patients showed a statistically 
significant improvement on CRQ-Dyspnoea (MD = 0.5 points, 95% CI 0.1 to 0.8 points, 
p < 0.01), CRQ-Fatigue (MD = 0.7 points, 95% CI 0.4 to 1.0 points, p < 0.01), and 
CRQ-Emotion (MD = 0.5 points, 95% CI 0.2 to 0.7 points, p < 0.01) scores with 
unsupervised exercise. Levels of heterogeneity were considered to be unimportant 
(CRQ-Dyspnoea, I2 = 36%; CRQ-Fatigue, I2 = 37%; CRQ-Emotion, I2 = 0%) (Figures 
4A-C). There was substantial heterogeneity for CRQ-Mastery scores (I2 = 93%, p < 
0.01). This could not be explained by any pre-specified clinical and methodological 
factors, hence meta-analysis was deemed inappropriate. One further trial reported 
CRQ as an outcome (25) in a COPD population, but domain data could not be obtained 
for meta-analysis.  
MRC Dyspnoea Scale: Meta-analysis of three trials (18, 19, 22) in COPD patients 
showed a statistically significant improvement in MRC breathlessness score with 
unsupervised exercise (MD = -0.3 points, 95% CI -0.5 to -0.1 points, p < 0.01) (Figure 
5). Statistical heterogeneity was not apparent (I2 = 0%). One further trial (19) reported 
on dyspnoea using BDI/TDI in COPD patients, and therefore was not included in the 
meta-analysis.  
Other reported outcomes: Anxiety and depression in COPD patients (14, 18, 23), 
asthma control (27, 28), CAT (16, 17), and SF-36 in COPD patients (18, 25) were 
reported as outcomes but the use of a mixture of different measurement tools and/or 
being unable to obtain suitable data deemed meta-analysis inappropriate.  
Healthcare utilisation 
Hospitalisations (respiratory cause), mortality and exacerbations: One trial presented 
data on respiratory cause hospital admissions, mortality and exacerbations (15), 
therefore a meta-analysis could not be performed for these outcomes. A further trial 
presented data on respiratory cause hospitalisations (21) but data could not be 
obtained for meta-analysis.  
Secondary Outcomes 
Hospitalisations (all cause): One trial presented data on all-cause hospitalisations (21), 
therefore a meta-analysis could not be performed for these outcomes.  
Other reported outcomes: Hospital length of stay in COPD patients (21), emergency 
department visits in COPD patients (15, 21), outpatient visits in COPD patients (15), 
aerobic fitness in either COPD or asthma populations (19, 25, 27-29), muscle strength 
in either COPD or asthma populations (17, 25, 28), physical activity levels in COPD 
patients (16, 22) were reported as outcomes but the use of different measurement 
tools, utilisation of differing outcome measurements, or not being able to obtain data 
across studies, meant these outcomes could not be meta-analysed. All trials reporting 
relevant outcomes which could not be included in meta-analyses have been 
narratively summarised in Table S5.  
Discussion 
Summary of main findings 
To our knowledge, this is the first review to have synthesised data from randomised 
trials assessing the effect of unsupervised exercise interventions on functional 
exercise capacity, quality of life, and health care use of people with obstructive lung 
disease in comparison to non-exercise based usual care. This systematic review 
provides evidence that unsupervised exercise interventions in addition to non-exercise 
usual care can improve the disease-specific quality of life of people with COPD by 
clinically meaningful amounts, but this is not seen with exercise capacity outcomes.  
Unfortunately, data were unavailable for meta-analyses from included studies of other 
obstructive lung diseases such as asthma, so the findings presented are only 
applicable to that of COPD. No studies of bronchiectasis patients met the inclusion 
criteria for this review.  
Interpretation of the results 
6MWT was the most commonly reported measure of exercise capacity (14, 15, 17, 18, 
20, 22, 25, 26). Based on a minimal clinically important difference (MCID) of 30 metres 
(32) the 22 metre 6MWT improvement with unsupervised exercise cannot be 
considered clinically meaningful for people with COPD. This is in contrast to 
established literature demonstrating that supervised exercise interventions are 
effective at increasing exercise capacity (1), which may indicate the importance of a 
supervision element.   
Whilst data synthesis from four trials (19, 21, 23, 24) suggests that unsupervised 
exercise may improve ISWT performance by a statistically significant amount, this 
effect fell below the MCID for COPD (47.5 m) (33) echoing the findings observed with 
6MWT. The meta-analysis for ISWT performance was heavily weighted by one large 
study which incorporated unsupervised exercise as part of a self-management 
programme (23), with a ‘light touch’ approach for prescribing exercise and ensuring 
adherence, which may limit intervention effectiveness. The larger estimate of effect 
seen in other included studies, which included a more formalised prescription, perhaps 
suggests that the lack of clinically meaningful improvement in ISWT with unsupervised 
exercise should be viewed with some caution.   
In terms of quality of life outcomes, synthesised data suggests that unsupervised 
exercise leads to statistical and clinically meaningful improvements in total scoring of 
SGRQ (15, 18, 21, 26) and domain scoring of CRQ (19, 22-24). Unsupervised exercise 
also improved MRC breathlessness score by -0.3 points (18, 19, 22), but this fell short 
of the MCID of -1 point (34). These findings are in keeping with those of a previous 
review which included supervised exercise training in people with COPD (35). It is 
important to note however, that due to unexplained heterogeneity, the effects of 
unsupervised exercise on the mastery domain of the CRQ are still unclear. 
Furthermore, there was evidence of heterogeneity in estimates of intervention effect 
on SGRQ. It would appear that the study of Bourbeau et al. (15) may have been a key 
contributor to the significant heterogeneity whereby a 12-month intervention was 
implemented. Despite reporting significant treatment effects at 4 months, this was not 
apparent at 12 months casting doubt on the longer-term impact of unsupervised 
interventions (15). It could be that the lack of formal prescription and adherence 
monitoring may have contributed to this lack of observed effect at the end of the 
intervention (15). Given the relative lack of eligible studies over 12 weeks long, further 
high-quality research is needed to establish the longer-term benefits of unsupervised 
exercise.  
There was a paucity of evidence reporting outcomes related to healthcare utilisation 
meaning meta-analysis was not possible. Considering the importance of healthcare 
utilisation to the future health outcomes of all chronic respiratory disease patients (36), 
it is imperative that more trials are conducted which examine the potential benefit of 
unsupervised exercise interventions on these outcomes.  
Strengths and limitations 
A key strength of this review is that it is the first to have comprehensively searched for 
and synthesised data from randomised controlled trials of unsupervised exercise 
interventions across all obstructive lung diseases. This is the first systematic review to 
report significant and clinically meaningful improvements in disease-specific quality of 
life in these patients. In doing so, this review followed a pre-planned and publicly 
available protocol. It is important to highlight that raw study data were obtained to 
increase the amount of studies in our analysis.  
A limitation of our review is that when writing the protocol, we did not expect such 
disparity between included trials in terms of how unsupervised exercise was defined, 
prescribed, monitored and reported. It is clear that the levels of heterogeneity seen 
across a number of reported outcomes may well be due to the diversity in methods of 
exercise prescription and support. Despite having success in requesting data for 
analyses, there were studies presenting relevant outcomes, which could not be 
obtained for meta-analysis. Two of which were asthma focussed (27, 28) meaning the 
findings of our meta-analysis are purely COPD focussed. However, a narrative 
summary of the reported effects within individual studies for which data could not be 
obtained has been tabulated to supplement the meta-analyses presented. Similarly, 
our searches were current as of April 2020 and there are ongoing studies which may 
have been eligible for inclusion had they been completed prior to this date. For 
example, Zanaboni et al. (37) are conducting a large multicentre randomised 
controlled trial with COPD patients to examine the effects of a longer-term 
unsupervised exercise intervention on health care utilisation, quality of life and 
exercise capacity. This study will be an important contribution to the area.  
Implications to practice 
Given the likely lower cost and time requirements with unsupervised exercise 
interventions, our review supports the potential use as part of the COPD treatment 
pathway. Supervised elements may need to be considered if the intervention is 
intended to maximise changes in exercise capacity but further head to head evidence 
of supervised versus unsupervised programmes (as done in (9, 10)) would be required 
to investigate this.  
Whilst substantial diversity among the specific interventions existed, the current data 
would suggest that incorporating formal prescription relating to basic programming 
principles (i.e. frequency, intensity, time, type), and facilitating compliance should be 
key considerations for practitioners. However, given the lack of consistency in how 
these factors have been included in research to date it is not possible to provide further 
clarity on how to best integrate these aspects of unsupervised exercise prescription 
for obstructive lung disease patients. 
Implications to research 
The quality of evidence presented within this review and meta-analysis is generally 
low. The poor reporting that was generally observed across the included studies in this 
review suggests future randomised controlled trials should work to Consolidated 
Standards of Reporting Trials (CONSORT) guidelines. 
Despite the apparent benefits of unsupervised exercise for people with COPD, higher-
quality large-scale randomised controlled trials are needed to examine the relative 
effectiveness of different approaches to prescription. The impact of further research 
on the existing evidence base can be highlighted by the confidence intervals of our 
point estimates. Although we report the overall magnitude of effects in some outcome 
measures to be clinically meaningful, the majority of the confidence intervals for these 
point estimates include between-group differences, which would not meet MCID’s. At 
the same time, the available evidence does not currently favour a clinically meaningful 
effect of unsupervised exercise on 6MWT, but the confidence interval does contain a 
change that would surpass the MCID. To build on the existing evidence and for 
comparison against supervised exercise, it would be advantageous for future studies 
to incorporate the most common assessments of functional exercise capacity (6MWT, 
ISWT) and disease-specific quality of life (i.e. SGRQ, CRQ), in addition to 
hospitalisation and exacerbation data.  
In order to maximise the translation of findings to applied practice, more studies should 
examine unsupervised exercise interventions for chronic lung diseases beyond 
COPD, across a wider range of disease severity, and should follow patients over 
longer periods of time (i.e. >12 weeks).  
Conclusion  
In conclusion our systematic review and meta-analysis provides evidence that 
unsupervised exercise interventions result in improvements in health-related quality of 
life, but not necessarily exercise capacity. However, further higher quality randomised 
trials are likely to have an important impact on our confidence in the estimates of effect, 
particularly to what extent these improvements are clinically meaningful. Despite our 
intentions to review the evidence in asthma and bronchiectasis, there remains a lack 
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Figure 1. Flow diagram of study selection.  
Figure 2. Trial-level data, effect estimates, and forest plot of comparison for change 
in 6MWT distance following an unsupervised exercise intervention versus usual care 
in studies reporting 6MWT for which data were able to be obtained (A), and for change 
in ISWT following an unsupervised exercise intervention versus usual care (B). Risk 
of bias legend: A) Random sequence generation (selection bias), B) Allocation 
concealment (selection bias), C) Blinding of participants and personnel (performance 
bias), D) Blinding of outcome assessment (detection bias), E) Incomplete outcome 
data (attrition bias), F) Selective reporting (reporting bias), G) Other bias. 
Figure 3. Trial-level data, effect estimates, and forest plot of comparison for change 
in SGRQ-Total (A), SGRQ-Symptoms (B), SGRQ-Activity (C), and SGRQ-Impact (D) 
scores following an unsupervised exercise intervention versus usual care in all studies 
reporting SGRQ-Total and domain scores with pre-specified subgroup analysis 
according to duration of interventions. Risk of bias legend: A) Random sequence 
generation (selection bias), B) Allocation concealment (selection bias), C) Blinding of 
participants and personnel (performance bias), D) Blinding of outcome assessment 
(detection bias), E) Incomplete outcome data (attrition bias), F) Selective reporting 
(reporting bias), G) Other bias. 
Figure 4. Trial-level data, effect estimates, and forest plot of comparison for change 
in CRQ-Dyspnoea (A), CRQ-Fatigue (B), and CRQ-Emotion (C) scores following an 
unsupervised exercise intervention versus usual care in all studies reporting CRQ 
domain scores. CRQ-Mastery scores were not meta-analysed due to substantial 
unexplained heterogeneity. Risk of bias legend: A) Random sequence generation 
(selection bias), B) Allocation concealment (selection bias), C) Blinding of 
participants and personnel (performance bias), D) Blinding of outcome assessment 
(detection bias), E) Incomplete outcome data (attrition bias), F) Selective reporting 
(reporting bias), G) Other bias. 
Figure 5. Trial-level data, effect estimates, and forest plot of comparison for change 
in MRC score following an unsupervised exercise intervention versus usual care. Risk 
of bias legend: A) Random sequence generation (selection bias), B) Allocation 
concealment (selection bias), C) Blinding of participants and personnel (performance 
bias), D) Blinding of outcome assessment (detection bias), E) Incomplete outcome 
data (attrition bias), F) Selective reporting (reporting bias), G) Other bias. 
  
 
 
